AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05000528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Actimetry
Description: once from inclusion for 2 weeks, second for 2 weeks starting 2 weeks after intervention
Study NCT05000528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: once from inclusion for 2 weeks, second for 2 weeks starting 2 weeks after intervention
Study NCT05489705 — intervention group
Intervention type: DRUG
Intervention: Mavacamten
Description: As per product label
Study NCT05489705 — intervention group
Intervention type: DRUG
Intervention: Non-mavacamten symptomatic oHCM therapy
Description: Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label
Study NCT06475560 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CCE arm
Description: Twice a week, patients will attend the in-hospital clinic in groups of five persons. They will bring their completed FIT sample, questionnaire, and the signed consent form. A project nurse will administer the capsules in the morning, and the patients can leave after. When the capsule investigation is completed, patients must return their belt and receiver to the Department of Surgery, OUH. After a few days, the patient will receive an electronic letter with the results and information regarding upcoming steps. Those with positive findings or an incomplete investigation will be given a new appointment according to the current clinical routine. A second questionnaire will be sent to the patient 2 weeks after the completed procedure.
Study NCT06475560 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: OC arm
Description: Patients will start bowel cleansing according to the instructions. They will bring their completed questionnaire and the signed consent form to the scheduled colonoscopy. They will continue to follow the routine clinical setup for outpatient colonoscopy and will only receive, by digital post, after 2 weeks from the procedure, an extra second questionnaire.
Study NCT05113264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 'Penny' via Memora Platform
Description: The overall objective of this study is to evaluate the feasibility and safety of a novel SMS text- based intervention of an Algorithmically Driven Augmented Intelligence chatbot, Penny. This chat bot will walk patients through how and when to take their oral chemotherapies, as well as provide real-time management of side effects Grade II or less, and escalate to the clinical team side effects of Grade III or more, as based on the Common Terminology Criteria for Adverse Events (CTCAE), for patients that have a gastrointestinal (GI) cancer.
Study NCT05830266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful with your Baby group-based therapist-guided intervention
Description: This 8-sessions long intervention is one of very few interventions that actively includes the baby in the therapy sessions. The intervention includes the following sessions: Becoming aware of the autopilot, Practice to really look at your baby, Getting back in touch with yourself, Responding sensitively to your baby, Taking care of yourself in the difficult moments, Distance and proximity: it's both part of it, Dealing with expectations of yourself and the environment and Mindful parenting: trial and error. The intervention is a group-based therapist-guided intervention via a video-conferencing tool (e.g., Zoom).
Study NCT05830266 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindful with your baby self-guided online intervention
Description: This 8-sessions long intervention includes the following sessions: Autopilot, Fresh view, At home in your body, Responsive versus reactive parenting, Kindness to yourself, Distance and proximity, Boundaries and taking care of yourself and Mindful parenting - day by day. The intervention is an individual self-guided online intervention.
Study NCT06487052 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard Catheter-Directed Low Dose Thrombolysis
Description: Using femoral or jugular vein access the mechanical blood clots fragmentation by PigTail 6F catheter circular rotational movements. For unilateral thromboembolism, the PigTail catheter is positioned in the obstructed branch of the pulmonary artery, 1 mg of alteplase is injected as a bolus, followed by a micro-jet injection of 1 mg/hour. For bilateral thromboembolism, the PigTail catheter is positioned in the pulmonary trunk with a bolus of 2 mg alteplase followed by an infusion of 2 mg/hour. The total duration of infusion will be 9 hours, the total dose of alteplase will be 10 mg for unilateral lesions and 20 mg for bilateral lesions. During the alteplase infusion, unfractionated heparin is continued with a target activated partial thromboplastin time (aPTT) of 50 to 60 seconds. After completion of the procedure, UFH therapy is continued for 24 hours, followed by a change to oral anticoagulants.
Study NCT06487052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Anticoagulation
Description: Therapy with UFH with targeted аPTT lasts for 24 hours (no more than 48 hours in total). Then the change to oral anticoagulants is performed
Study NCT06104293 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Grass Pollen Allergen Exposure
Description: After the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3).~Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations.
Study NCT05305716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Pilates Training
Description: The group that received telerehabilitation and telerehabilitation-based pilates training.
Study NCT05305716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The group who received breathing and relaxation exercises with a home program.
Study NCT06642480 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Post Operative Analgesia
Description: administering 100 mg of intravenous tramadol 30 minutes before the operation is completed
Study NCT06642480 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Post Operative Analgesia
Description: VAS of 63 patients was determined by injecting tramadol at a dose of 100 mg 30 minutes before the operation was completed. It was observed in the recovery room at 30, 60, and 120 minutes.
Study NCT05910827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-001
Description: HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly
Study NCT05910827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks
Study NCT05665647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: SIM0417/ritonavir and itraconazole
Description: SIM0417/Ritonavir: Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1-Day2, Day9-Day10, BID; Day3,Day11(once only in the morning); Itraconazole：Dose: 200mg once；Day6-Day13, QD
Study NCT05665647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: SIM0417/ritonavir and rifampicin
Description: SIM0417/Ritonavir:Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1,Day11(once only in the morning); Rifampicin：Dose: 0.6g once; Day4-Day12, QD
Study NCT05665647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3: SIM0417/ritonavir and midazolam
Description: SIM0417/Ritonavir: 750 mg SIM0417 coadministered with 100 mg ritonavir, Day3-Day6, BID; Day7(once only in the morning) Midazolam：Dose: 2mg once; Day1, Day6, QD
Study NCT06157424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thread Embedding Acupuncture
Description: Thread Embedding Acupuncture is applied at acupoints including CV-12, CV-13, ST-36, PC-6, BL-17, BL-18, BL-21 on both sides of the body every 2 weeks, totaling 2 sessions over 4 weeks of intervention.
Study NCT06157424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture is administered using adhesive patches with small needles (0.25 x 1.3 mm) placed at acupoints TF4, AH6, CO12, CO4, CO2 once a week, totaling 4 sessions over the 4-week intervention period.
Study NCT05910827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
Study NCT05041101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV
Study NCT05041101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grapiprant
Description: Given PO
Study NCT05817045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RD-X19
Description: Investigational device that uses safe electromagnetic energy to target the oropharynx.
Study NCT05817045 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
Study NCT06334939 — intervention group
Intervention type: DEVICE
Intervention: Bispectral Index Monitoring
Description: Study patients will undergo perioperative bispectral index and BIS suppression ratio (SR) monitoring under anesthesia. The lowest BIS and BIS SR values and the values taken at 10-minute intervals will be recorded throughout the case.~The Richmond agitation scale will be calculated in the recovery room after anesthesia.
Study NCT05036278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
Description: Dosage Levels:~* 40 IU/kg/dose two times per week~* 50 IU/kg/dose every 5 days~* 60 IU/kg/dose, Less frequent dosing (e.g. every 7 days), the total recommended maximum dose/infusion is 6000 IU.
Study NCT06157424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of proton pump inhibitors, additional antacids as needed, and lifestyle modifications.
Study NCT06008808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is provided by Incyte Corporation.
Study NCT05652855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHB088C for Injection
Description: MHB088C for Injection, an antibody drug-conjugated molecule (ADC)
Study NCT05148624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embryo transfer
Description: immediate ambulation after embryo transfer
Study NCT05146908 — intervention group
Intervention type: BIOLOGICAL
Intervention: 2 Blood samples from arterial and/or central venous catheters
Description: 5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
Study NCT05148624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: embryo transfer
Description: immediate ambulation after embryo transfer
Study NCT06161753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy
Description: CFT is an individualised, combined physical and behavioural approach specifically developed to target the multidimensional complexity of persistent LBP. CFT utilises a multidimensional clinical reasoning framework that enables the clinician to identify both modifiable and non-modifiable biopsychosocial factors (i.e. physical, cognitive, emotional, social, lifestyle and health comorbidities) underlying an individual's LBP. CFT targets these factors by: (1) helping the patient 'make sense of their pain' from a biopsychosocial perspective, (2) build confidence to engage in valued activities through functional movement training and (3) adopt positive lifestyle behaviours (O'Sullivan et al., 2018).~Participants will receive approximately 7 treatment sessions over a 13-week period, although this will vary depending on participant needs, in line with the individualised nature of the intervention. Participants will be provided a booster session at 26 weeks to reinforce self-management.
Study NCT06548685 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Grafting
Description: Bone grafting in some sites and Vegetable Ivory Grafting in Parallel sites
Study NCT06548685 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vegetable Derived
Description: Tooth extraction followed by socket preservation with vegetable ivory
Study NCT05969522 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GlucoCorticoid
Description: The high-risk group: methylprednisolone intravenous 15-30mg/kg/d (Max.500mg/d)\*3 days , with 2 courses, interval 5-7 days;Oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d) during methylprednisolone impact interval and later stage, with the first reduction after 2-4 weeks. The dose was reduced once every 3 weeks in the first 3 months, and once every 4 weeks in the next 3 months, with a reduction of 5-10mg/ day each time; Rituximab：375 mg/m2/ time, once a week for 4 times;Intravenous cyclophosphamide 7.5-10mg/kg.d\*2 days(Max.500mg/d), once every 4 weeks, twice in total, at the 8th and 12th week.The medium-low risk group: methylprednisolone was the same dose as before, but only with 1 course, then followed by oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d), divided into three times for 3 weeks, and then changed to morning daily; The dose was reduced as the high-risk group ;Rituximab was the same dose as before.
Study NCT05969522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlucoCorticoid
Description: The high-risk group: methylprednisolone intravenous 15-30mg/kg/d (Max.500mg/d)\*3 days , with 2 courses, interval 5-7 days;Oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d) during methylprednisolone impact interval and later stage, with the first reduction after 2-4 weeks. The dose was reduced once every 3 weeks in the first 3 months, and once every 4 weeks in the next 3 months, with a reduction of 5-10mg/ day each time; Rituximab：375 mg/m2/ time, once a week for 4 times;Intravenous cyclophosphamide 7.5-10mg/kg.d\*2 days(Max.500mg/d), once every 4 weeks, twice in total, at the 8th and 12th week.The medium-low risk group: methylprednisolone was the same dose as before, but only with 1 course, then followed by oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d), divided into three times for 3 weeks, and then changed to morning daily; The dose was reduced as the high-risk group ;Rituximab was the same dose as before.
Study NCT05457998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flutemetamol F18 Injection
Description: PET imaging of Abeta amyloid
Study NCT05457998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]-RO6958948 Injection
Description: PET imaging of Tau aggregates
Study NCT05457998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]-MK-6240 Injection
Description: PET imaging of Tau aggregates
Study NCT05146908 — intervention group
Intervention type: OTHER
Intervention: Echography
Description: In 3 steps:~* before initiation of enteral nutrition~* 4h after initiation of enteral nutrition~* After 24 hours of enteral nutrition
Study NCT04953884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: wilate
Description: wilate is a plasma-derived, stable, highly purified, double virus inactivated concentrate of freeze-dried active VWF and factor VIII (FVIII) prepared from cryoprecipitate and intended for the treatment of patients with von Willebrand disease (VWD) and/or haemophilia A
Study NCT04838626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]CTT1057
Description: PET/CT imaging with \[18F\]CTT1057
Study NCT05146908 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: At inclusion:~Calculation of severity scores; collection of reason for admission and demographic data; main comorbidities and treatments administered; the time between admission and nutritional recovery; risk factors for gastroparesis; current organ failure and supplements. Presence of parenteral nutrition, ongoing carbohydrate intake. Caloric objective.~Within the first 24 hours, collection of:~* echographic parameters at H0, H4 and H24~* venous congestion parameters~* biological parameters within 24 hours Constitution of a biobank (at H0 and H24)~Within the first 7 days, collection of:~* the occurrence or not of the primary endpoint (and time to occurrence).~* symptoms of gastrointestinal dysfunction~Within 30 days, collection of:~* organ failure and replacement over the period, and mortality.~* the occurrence or not of ventilator-associated lung disease (VAPD). Each patient is followed for 30 days. Survival will be assessed at 30 days before discharge from the study.
Study NCT05443126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0031
Description: EP0031 is a potent next-generation selective RET-inhibitor (SRI)
Study NCT06101290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablative local therapy
Description: Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
Study NCT03498014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic analysis allowing personalized opioid prescription
Description: Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)
Study NCT03498014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard opioid prescription
Description: Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)
Study NCT04373603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
Study NCT04373603 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: sodium chloride and water for use as control
Study NCT04373603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid
Description: Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
Study NCT04373603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
Study NCT05137938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine (IN)
Description: A sterile form of ketamine will be administered intranasally twice weekly for four weeks. Dosing schedule will be determined based on patient's weight using a specialized formula. Patients will be started at the lowest dose during the first treatment session. Dose will be titrated further to therapeutic dose in the following sessions. The dose will be adjusted if patients do not tolerate full therapeutic doses. After receiving the second treatment of each week, participants will be seen by a study physician to determine dosing for the following week. Patients will be monitored by trained personnel for the full duration of the 2 hour supervision period. Vital signs and physical symptoms will be monitored consistently and measurements taken every 30 minutes. Appropriate medications will be provided to manage treatment-related side effects and any adverse events. Labetalol will be used in the management of treatment-related transient hypertension as needed.
Study NCT05318521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen
Study NCT05318521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen modified release tablet 800 mg
Description: Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-\[4-(2-methylpropyl) phenyl\] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).
Study NCT05425771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti Reflux Mucosa Ablation
Description: Mucosa ablation with Argon plasma coagulation performed in inversion at the gastroesophageal junction in a crescent or horseshoe shape over a width of 1.5 - 2 cm in patients with refractory reflux symptoms
Study NCT05595525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1064NM pico Laser
Description: There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
Study NCT05595525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755NM pico Laser
Description: There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
Study NCT05777928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: Sleeve gastrectomy involves vertical resection of a major part of the stomach, and a tubular remnant is retained along the lesser curvature.
Study NCT05777928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OverStitch™ Endoscopic Suturing System
Description: Overstitch endoscopic procedure makes a review of gastro-jejunal anastomosis reducing surgical complications